These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17956948)

  • 1. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes.
    Juurinen L; Tiikkainen M; Häkkinen AM; Hakkarainen A; Yki-Järvinen H
    Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E829-35. PubMed ID: 17090752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
    Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
    Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.
    Iozzo P; Hallsten K; Oikonen V; Virtanen KA; Parkkola R; Kemppainen J; Solin O; Lonnqvist F; Ferrannini E; Knuuti J; Nuutila P
    Diabetes Care; 2003 Jul; 26(7):2069-74. PubMed ID: 12832315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.
    Gastaldelli A; Miyazaki Y; Pettiti M; Santini E; Ciociaro D; Defronzo RA; Ferrannini E
    J Clin Endocrinol Metab; 2006 Mar; 91(3):806-12. PubMed ID: 16352689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes.
    Llauradó G; Sevastianova K; Sädevirta S; Hakkarainen A; Lundbom N; Orho-Melander M; Groop PH; Forsblom C; Yki-Järvinen H
    J Clin Endocrinol Metab; 2015 Feb; 100(2):607-16. PubMed ID: 25405502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
    Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
    Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
    Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism.
    Yang S; Luo T; Zhou H; Lv Q; Liu L; Zhang W; Gao R; Chen S; Xia W; Luo M; Cheng Q; Li Q
    Endocrinology; 2014 Mar; 155(3):941-50. PubMed ID: 24424059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
    Kotronen A; Juurinen L; Tiikkainen M; Vehkavaara S; Yki-Järvinen H
    Gastroenterology; 2008 Jul; 135(1):122-30. PubMed ID: 18474251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
    Mayerson AB; Hundal RS; Dufour S; Lebon V; Befroy D; Cline GW; Enocksson S; Inzucchi SE; Shulman GI; Petersen KF
    Diabetes; 2002 Mar; 51(3):797-802. PubMed ID: 11872682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
    Ryysy L; Häkkinen AM; Goto T; Vehkavaara S; Westerbacka J; Halavaara J; Yki-Järvinen H
    Diabetes; 2000 May; 49(5):749-58. PubMed ID: 10905483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
    Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
    Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.